Nationwide registry for autoimmune liver diseases in Canada

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Canadian Network for Autoimmune Liver Disease (CaNAL) is a longitudinal observational cohort study that aims to create a comprehensive registry of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome. By collecting and analyzing patient data from major Canadian medical centers, the study seeks to enhance understanding of these rare and progressive liver diseases. The focus is on high-quality long-term follow-up, which will provide valuable insights into patient characteristics and disease progression over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of Primary Biliary Cholangitis and/or Autoimmune Hepatitis

Exclusion Criteria:

* Less than 18 years of age

Where it's running

• University of Alberta Hospital
  Edmonton, Alberta, Canada Recruiting
• London Health Sciences Centre - University Hospital
  London, Ontario, Canada Recruiting
• The Ottawa Hospital
  Ottawa, Ontario, Canada Recruiting
• Toronto General Hospital
  Toronto, Ontario, Canada Recruiting
• Centre hospitalier de l'Université de Montréal
  Montreal, Quebec, Canada Recruiting
• Université de Sherbrooke
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Bettina Hansen, PhD — University Health Network, Toronto General Hospital
• Study coordinator: Surain Roberts, AB
• Email: surain.roberts@uhn.ca
• Phone: 613 291 5039

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inebilizumab for Autoimmune Hepatitis: a study in adults

  This trial tests whether inebilizumab can be safely used in adults with autoimmune hepatitis and whether it helps reduce liver disease activity and the need for steroids.

  Recruiting at 35 sites Phase 3 Amgen · Little Rock, Arkansas and 35 other locations · NCT07598825

• Pediatric autoimmune hepatitis: can a vegan diet reduce reliance on immunosuppressants

  In children with autoimmune hepatitis, this study tests whether adding a vegan diet for six months to standard treatment can help achieve liver disease remission compared with a standard high-protein diet.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT07118657

• Identifying liver disease-specific gut microbiomes

  This study is trying to find out if certain gut bacteria are linked to chronic liver diseases in adults, including autoimmune hepatitis and primary biliary cholangitis, by analyzing blood and stool samples from patients and their household members.

  Recruiting Chungnam National University Hospital · Daejeon, Jung-gu · NCT06519162

• Using Siplizumab to prevent immune issues in liver transplant patients with autoimmune liver disease

  This study is testing if a new medication called siplizumab can help prevent immune problems in adults with autoimmune liver disease who are getting a liver transplant.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06455280

• Using Belimumab to treat Autoimmune Hepatitis

  This study is testing if Belimumab can help people with autoimmune hepatitis feel better and improve their liver function when other treatments haven't worked.

  Recruiting at 6 sites Phase 2 University Health Network, Toronto · Calgary, Alberta and 5 other locations · NCT06381453

• Comparing Mediterranean and Western diets for fatigue in autoimmune hepatitis patients

  This study is testing whether following a Mediterranean diet or a Western diet can help reduce fatigue and improve quality of life for people with autoimmune hepatitis.

  Recruiting Indiana University · Indianapolis, Indiana · NCT06250309

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.